A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts
Portfolio Pulse from Benzinga Insights
NeuroPace (NASDAQ:NPCE) has been evaluated by 4 analysts over the last three months, showing a diverse range of opinions. The average 12-month price target for NPCE is now $14.75, up from $9.67, indicating a positive outlook. The company, focusing on medical devices for epilepsy, reported a 47.23% revenue growth and a net margin of -44.18%. Despite a high debt-to-equity ratio of 4.38, its market capitalization and revenue growth surpass industry averages.
February 22, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroPace has received mixed analyst ratings but an increased average price target to $14.75, indicating a positive sentiment. The company's strong revenue growth and market position are positive, but high debt levels and below-average ROE and ROA present challenges.
The increase in the average price target reflects a positive sentiment among analysts, which could lead to short-term price appreciation. However, the company's financial health, indicated by high debt levels and poor ROE/ROA, could temper investor enthusiasm. The strong revenue growth is a significant positive factor that might outweigh the negatives in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100